Effect of Rectal Administration of Breast Milk on Gut Microbiota in Preterm Infants (premic)
Effect of Rectal Administration of Human Milk on Gut Microbiota and Clinical Outcomes in Preterm Infants: A Randomized Controlled Study
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Preterm infants are highly vulnerable to alterations in gut microbiota due to immaturity, delayed enteral feeding, antibiotic exposure, and environmental factors. Early-life dysbiosis has been associated with adverse outcomes including necrotizing enterocolitis, sepsis, and impaired immune development. Strategies to promote healthy microbiota colonization in preterm infants are therefore of significant clinical interest.
Breast milk contains beneficial bacteria, prebiotics, and bioactive components that play a critical role in shaping neonatal gut microbiota. However, in the early postnatal period, especially in very preterm infants, enteral feeding may be limited or delayed. Alternative routes of exposure to breast milk components may offer a potential strategy to influence microbiota development.
This randomized controlled study aims to investigate the effects of rectal administration of maternal breast milk on gut microbiota in preterm infants. Participants will be randomly assigned to receive either rectal maternal breast milk or normal saline. Stool samples will be collected at predefined time points to assess microbiota composition.
The study is designed to explore whether rectal exposure to breast milk can modulate early microbial colonization and provide a feasible, safe, and innovative approach to support gut microbiota development in preterm infants.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
Preterm infants with a gestational age ≤32 weeks and birth weight ≤1500 g
Infants without meconium passage within the first 48 hours of life
Infants whose parents have provided written informed consent
Exclusion Criteria:
nfants with major congenital anomalies
Infants with gastrointestinal system anomalies
Infants in whom administration of maternal breast milk is contraindicated
Infants whose parents do not provide consent for participation
Infants who die within the first 72 hours of life
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Rectal irrigation with maternal breast milk
Rectal irrigation will be performed starting 48 hours after birth, twice daily for 5 consecutive days at 09:00 and 21:00.
A 6 Fr feeding tube, 5 mL syringe, thermostatically controlled water bath (set at 37°C), sterile water-based lubricant, and sterile gloves will be used.
The enema volume will be calculated as 5 mL/kg and warmed to 37°C.
One end of the feeding tube will be connected to the syringe, and the other end will be gently inserted into the rectum after lubrication.
The solution will be administered slowly over approximately 3 minutes, and the tube will then be carefully removed.
Maternal breast milk will be used for rectal irrigation.
|
Maternal breast milk will be used for rectal irrigation .
Rectal irrigation will be performed starting 48 hours after birth, twice daily for 5 consecutive days at 09:00 and 21:00.
A 6 Fr feeding tube, 5 mL syringe, thermostatically controlled water bath (set at 37°C), sterile water-based lubricant, and sterile gloves will be used.
The enema volume will be calculated as 5 mL/kg and warmed to 37°C.
One end of the feeding tube will be connected to the syringe, and the other end will be gently inserted into the rectum after lubrication.
The solution will be administered slowly over approximately 3 minutes, and the tube will then be carefully removed.
|
|
Active Comparator: Rectal irrigation with normal saline
Rectal irrigation will be performed starting 48 hours after birth, twice daily for 5 consecutive days at 09:00 and 21:00.
A 6 Fr feeding tube, 5 mL syringe, thermostatically controlled water bath (set at 37°C), sterile water-based lubricant, and sterile gloves will be used.
The enema volume will be calculated as 5 mL/kg and warmed to 37°C.
One end of the feeding tube will be connected to the syringe, and the other end will be gently inserted into the rectum after lubrication.
The solution will be administered slowly over approximately 3 minutes, and the tube will then be carefully removed.Normal saline will be used for rectal irrigation as an active comparator.
|
Rectal irrigation will be performed starting 48 hours after birth, twice daily for 5 consecutive days at 09:00 and 21:00.
A 6 Fr feeding tube, 5 mL syringe, thermostatically controlled water bath (set at 37°C), sterile water-based lubricant, and sterile gloves will be used.
The enema volume will be calculated as 5 mL/kg and warmed to 37°C.
One end of the feeding tube will be connected to the syringe, and the other end will be gently inserted into the rectum after lubrication.
The solution will be administered slowly over approximately 3 minutes, and the tube will then be carefully removed.
Normal saline will be used for rectal irrigation as an active comparator.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Gut microbiota composition in preterm infants
Aikaikkuna: 1 year
|
Gut microbiota composition will be analyzed using stool samples collected from preterm infants at 7 days and 1 month of life, including assessment of microbial diversity and relative abundance of bacterial taxa, to evaluate differences between study groups.
|
1 year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Time to full enteral feeding
Aikaikkuna: 1 year
|
Time to achieve full enteral feeding will be defined as the number of days from birth until the infant tolerates full enteral nutrition without the need for parenteral nutrition.
|
1 year
|
|
Feeding intolerance
Aikaikkuna: 1 year
|
Feeding intolerance will be defined as the occurrence of bilious emesis, gastric residuals, visibly bloody stools, abdominal distension or tenderness, abdominal discoloration, gastric residual volume exceeding 50% of the previous feeding volume, emesis occurring three or more times within a 24-hour period, or clinical or radiological evidence of necrotizing enterocolitis (NEC).
|
1 year
|
|
Necrotizing enterocolitis
Aikaikkuna: 1 year
|
Necrotizing enterocolitis will be diagnosed according to modified Bell's criteria stage II or higher.
|
1 year
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Suoliston sairaudet
- Synnytystyö, ennenaikainen
- Synnytystyön komplikaatiot
- Raskauden komplikaatiot
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Gastroenteriitti
- Enterokoliitti
- Ennenaikainen Synnytys
- Enterokoliitti, nekrotisoiva
Muut tutkimustunnusnumerot
- PREMIC-2026
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .